Pearl River Capital, LLC Biocryst Pharmaceuticals Inc Transaction History

Pearl River Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $53,697 - $72,618	5,114 Added 24.92%	25,637 $294,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $221,443 - $303,945	20,523 New	20,523 $259,000
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $356,272 - $807,371	-45,155 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $130,339 - $222,794	11,275 Added 33.28%	45,155 $734,000
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $49,080 - $67,869	4,390 Added 14.89%	33,880 $469,000
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $439,643 - $546,073	-30,939 Reduced 51.2%	29,490 $424,000
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $469,680 - $852,345	49,440 Added 449.9%	60,429 $955,000
Q4 2019 Feb 12, 2020	BUY	$1.59 - $3.45 $17,472 - $37,912	10,989 New	10,989 $38,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.